JBS Launches $37M Biotech Hub for Alternative Proteins
JBS has inaugurated a $37M biotech centre focusing on the production of 'superproteins' including microbial and cultivated proteins, aimed at precision nutrition and supplements. This facility is a significant investment in JBS's strategy to innovate in the alternative protein sector, a response to the evolving food landscape and consumer demands.
Theia Market Signal Identification - AI Assisted
JBS has opened a 4,000 sq m biotech facility dedicated to the development of 'superproteins' for the food and supplement markets. This investment, part of a broader $100M commitment following the acquisition of BioTech Foods, emphasizes the company's focus on precision nutrition and innovative food solutions.
The centre will utilize next-generation sequencers and advanced molecular analyses to enhance production methods. JBS aims to optimize the agro-industrial chain through a circular economy model, transforming co-products into valuable ingredients.
The facility also plans to create a biobank for biological sample preservation, supporting research and development efforts. This strategic move aligns with the increasing demand for alternative proteins amidst a changing global food landscape.
Comments